A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy.

TitleA chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy.
Publication TypeJournal Article
Year of Publication2010
AuthorsPethe K, Sequeira PC, Agarwalla S, Rhee K, Kuhen K, Phong WYee, Patel V, Beer D, Walker JR, Duraiswamy J, Jiricek J, Keller TH, Chatterjee A, Tan MPing, Ujjini M, Rao SPS, Camacho L, Bifani P, Mak PA, Ma I, S Barnes W, Chen Z, Plouffe D, Thayalan P, Ng SHwee, Au M, Lee BHeng, Tan BHuat, Ravindran S, Nanjundappa M, Lin X, Goh A, Lakshminarayana SB, Shoen C, Cynamon M, Kreiswirth B, Dartois V, Peters EC, Glynne R, Brenner S, Dick T
JournalNat Commun
Volume1
Pagination57
Date Published2010 Aug 24
ISSN2041-1723
KeywordsAdenosine Triphosphate, Antitubercular Agents, Glycerophosphates, Imidazoles, Models, Biological, Mycobacterium tuberculosis
Abstract

Candidate antibacterials are usually identified on the basis of their in vitro activity. However, the apparent inhibitory activity of new leads can be misleading because most culture media do not reproduce an environment relevant to infection in vivo. In this study, while screening for novel anti-tuberculars, we uncovered how carbon metabolism can affect antimicrobial activity. Novel pyrimidine-imidazoles (PIs) were identified in a whole-cell screen against Mycobacterium tuberculosis. Lead optimization generated in vitro potent derivatives with desirable pharmacokinetic properties, yet without in vivo efficacy. Mechanism of action studies linked the PI activity to glycerol metabolism, which is not relevant for M. tuberculosis during infection. PIs induced self-poisoning of M. tuberculosis by promoting the accumulation of glycerol phosphate and rapid ATP depletion. This study underlines the importance of understanding central bacterial metabolism in vivo and of developing predictive in vitro culture conditions as a prerequisite for the rational discovery of new antibiotics.

DOI10.1038/ncomms1060
Alternate JournalNat Commun
PubMed ID20975714
PubMed Central IDPMC3220188